Patent ID: 9506121
Filing Date: 2016-11-29
CPC Classification: C12Q

Claim Text:
1. A method for selecting a treatment for a patient having a human immunodeficiency virus (HIV) infection, comprising: a) determining a length of one or more variable regions of an envelope protein of an HIV from the patient or a number of glycosylation sites on the envelope protein of the HIV; b) comparing the length of the one or more variable regions of the envelope protein of the HIV or the number of glycosylation sites on the envelope protein of the HIV to the length of one or more corresponding variable regions of an envelope protein of a reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, respectively; c) determining that the HIV is likely to have reduced susceptibility to a CD4-blocking entry inhibitor if the one or more variable regions of the HIV are shorter than the corresponding variable regions of the reference HIV envelope protein or the HIV envelope protein has fewer glycosylation sites than the reference HIV envelope protein, wherein the CD4 -blocking entry inhibitor binds to the CD4 receptor; and d) treating the patient with an effective amount of the CD4-blocking entry inhibitor if the HIV is determined in step a) to be likely to be susceptible to the CD4-blocking entry inhibitor, or treating the patient with an effective amount of a different inhibitor if the HIV is determined in step a) to be likely to have reduced susceptibility to the CD4-blocking inhibitor.